In 2023, the share of corresponding/leading author in scientific publications in drug discovery in China was slightly below 98.51%. From 2024 to 2028, forecasts indicate a steady increase, with minor year-on-year growth. The increase is modest, showing a consistent strengthening of China's role in drug discovery leadership within academic publishing, reflecting an upward trajectory. The upward CAGR illustrates a solidifying position over the five-year forecast period.
Future trends to watch include:
- The impact of international collaborations on these figures.
- Government policies supporting domestic research and development.
- Technological advancements and their influence on the authorship landscape.
